.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05A_ParathyroidHormonesAndAnalogues.H05AA03_ParathyroidHormone.ParathyroidHormone .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05A_ParathyroidHormonesAndAnalogues.H05AA03_ParathyroidHormone.ParathyroidHormone| name: | ParathyroidHormone |
| ATC code: | H05AA03 | route: | subcutaneous |
| n-compartments | 1 |
Parathyroid hormone (PTH) is an endogenous peptide hormone used as a diagnostic agent and as recombinant formulations (e.g., teriparatide) for osteoporosis treatment. Full-length recombinant PTH (rhPTH 1-84, ATC code H05AA03) is approved for hypoparathyroidism. Its actions include increasing blood calcium levels by stimulating osteoclasts, renal calcium reabsorption, and activating vitamin D.
Pharmacokinetic parameters following a single subcutaneous administration of recombinant human parathyroid hormone (rhPTH 1-84) 100 μg in healthy adult subjects, mixed sex.
Stratford, R, et al., & Ponnapakkam, T (2014). Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct. Journal of pharmaceutical sciences 103(2) 768–775. DOI:10.1002/jps.23843 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24399637
Liu, Y, et al., & Shi, S (2014). Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects. Clinical therapeutics 36(6) 940–952. DOI:10.1016/j.clinthera.2014.03.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24793535
Liu, Y, et al., & Zeng, F (2012). Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. Basic & clinical pharmacology & toxicology 110(2) 154–161. DOI:10.1111/j.1742-7843.2011.00768.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21771277